GlassScriptPhysician profile
Sydney Ammann
NPI 1477228880
$2,159.38
in general payments reported to CMS, 2019-2025
31 companies · $674 in 2025
The $674 reported for 2025 was more than what 80% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $70.05 · 2022: $407 · 2023: $584 · 2024: $425 · 2025: $674.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,683.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,682.64 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $403.65 | 2021-2025 | |
| Novo Nordisk INC | $298.53 | 2022-2025 | Ozempic, Rybelsus |
| Astrazeneca Pharmaceuticals LP | $243.92 | 2022-2025 | Farxiga, Airsupra, Breztri |
| Boehringer Ingelheim Pharmaceuticals, INC. | $203.68 | 2021-2025 | Jardiance |
| Lilly USA, LLC | $142.37 | 2022-2025 | Jardiance, Lyumjev, Baqsimi |
| Pfizer INC. | $86.00 | 2024-2025 | |
| Boston Scientific Corporation | $79.26 | 2022 | |
| Merck Sharp & Dohme LLC | $60.68 | 2022-2024 | Gardasil 9, Vaxneuvance, Verquvo |
| Amgen INC. | $54.35 | 2023-2025 | Otezla, Repatha, Krystexxa |
| Dexcom, INC. | $50.46 | 2024 | Dexcom G6 Transmitter |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $43.23 | 2022-2023 | Xifaxan |
| Glaxosmithkline, LLC. | $34.84 | 2023-2024 | Trelegy Ellipta |
| Sumitomo Pharma America, INC. | $34.63 | 2023 | Gemtesa |
| Cranial Technologies, INC | $34.10 | 2023-2025 | Doc Band |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $33.74 | 2025 | Caplyta |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biohaven Pharmaceutical Holding Company LTD. | $33.32 | 2022 | |
| Exact Sciences Corporation | $32.50 | 2023 | Cologuard Collection Kit |
| Medtronic, INC. | $31.56 | 2023-2025 | Inceptiv, Closurefast |
| Janssen Pharmaceuticals, INC | $28.99 | 2023 | Invega Sustenna |
| Gilead Sciences, INC. | $26.84 | 2025 | |
| Tms Neurohealth Centers INC. | $24.65 | 2025 | Tms Neurohealth Centers INC. |
| Teva Pharmaceuticals USA, INC. | $21.29 | 2022 | |
| Verona Pharma, INC. | $21.28 | 2025 | Ohtuvayre |
| Xeris Pharmaceuticals, INC. | $21.08 | 2024 | Keveyis |
| Aerin Medical INC. | $18.76 | 2025 | |
| Kowa Pharmaceuticals America, INC. | $17.90 | 2025 | Zoryve |
| Phathom Pharmaceuticals, INC. | $17.15 | 2025 | Voquezna |
| Seqirus USA INC | $16.43 | 2025 | Flucelvax, Fluad |
| Alexion Pharmaceuticals, INC. | $16.39 | 2025 | Strensiq |
| Amneal Pharmaceuticals LLC | $14.52 | 2025 | Unithroid |
| Viiv Healthcare Company | $13.28 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sydney Ammann listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.